Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gadopiclenol - Guerbet

Next Previous
Drug Profile

Gadopiclenol - Guerbet

Alternative Names: EluciremTM; G03277; P03277; VUEWAY; Vueway

Latest Information Update: 28 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guerbet
  • Developer Bracco Imaging; Guerbet
  • Class Diagnostic agents; Gadolinium-containing contrast agents; Macrocyclic compounds; Propylamines; Pyridines
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed CNS disorders
  • Registered Breast disorders; Genitourinary disorders; Kidney disorders; Liver disorders; Lung disorders; Musculoskeletal disorders; Pancreatic disorders
  • Phase III Arterial occlusive disorders; Brain cancer; Unspecified
  • Phase II Liver cancer

Most Recent Events

  • 28 Jul 2026 Phase-III clinical trials in Arterial occlusive disorders (Diagnosis) in Hungary (IV) (CTIS2024-518835-13-00, NCT07348640)
  • 17 Apr 2026 Registered for Breast disorders (Diagnosis, In adults, In children, In adolescents) in Canada (IV)
  • 17 Apr 2026 Registered for CNS disorders (Diagnosis, In adults, In adolescents, In children) in Canada (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top